United Conference of Drug Development and Industrial Pharmacy

Theme : The Novel and Contemporary Research in Drug Development and Industrial Pharmacy

Webinar on Drug Development and Industrial Pharmacy | April 7, 2021

About The Conference

On behalf of United Conferences, we are overwhelmed to welcome all the interested participants to attend “United Conference of Drug Development and Industrial Pharmacy” Webinar Event on April 7th, 2021. This conference boats of a huge variety of Keynote presentations, Plenary talks, Poster presentations and Career development programs.

United Conference on Drug Development and Industrial Pharmacy aims to bring together a significant number of leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Drug Development and Industrial Pharmacy. It is a foremost integrative platform for researchers, educators and practitioners alike to present and explore the latest innovations, trends, and concerns as well as practical challenges encountered and solutions adopted in the fields of Drug Development and Industrial Pharmacy.

Keynotes

Executive Director at Ketotic Hypoglycemia International, Committee member at the European Health Parliament, Patient Representative at the European Medicines Agency, Rare2030 EURORDIS, Europe

CEO GCP Central B.V.,Amsterdam, North Holland, Netherlands

Senior Vice President, Operations at Zosano Pharma, California, USA

Eden Lord

Founder & CEO at My City Med, Founder of The Civitas Foundation, USA

Qihan Dong MD, PhD

Director, Chinese Medicine Anti-cancer Evaluation Program, Sydney Medical School The Faculty of Medicine and Health, The University of Sydney, Australia

Faculty member at Roswell Park Comprehensive Cancer Center, Roswell Park Cancer Institute, USA

Jim Hauske

President and founder at Sensor Pharma, United States

Jeff Lord, MSM

Chief Technology Officer (CTO) My City Med, USA

James T. O'Donnell

Pharmacologist Drug Expert, Associate Professor at Rush Medical College, United States

Director, Biomarkers at PPD, USA

Dr. Nalini kanta Sahoo

Principal, SRM Modinagar college of Pharmacy, Delhi-NCR campus, India

AC Matin

Professor at Stanford University, United States

Speakers

Virtual Exhibitors

PRA Consultancy

Professionals Regulatory Affairs (PRA) Consultancy

ASTE Logo

ASTE Pharmaceuticals, Medical & Laboratory Supplies

TGMP Consulting

CliniPro Trials

Webinar Registration Charges

Who Can Attend

  • Deans, Directors, CEO of an Organization
  • Business Development Managers
  • Chief Scientific Officers
  • R&D Researchers from Biosimilar and Biologic Industries
  • PhD Scholars
  • Professors, Associate Professors, Assistant Professors
  • Drug Development Discovery Companies
  • Association, Association Presidents and Professionals
  • Formulation and Pharma Manufacturing Companies
  • Business Entrepreneurs
  • Medical Software Developing Companies
  • Manufacturing Medical Devices Companies
  • Intellectual Property Attorneys
  • Noble laureates in Health Care and Medicine
  • Pharmacists
  • Bio-instruments and Bio-informatics Professionals
  • Research Institutes and members
  • Pharmacy Institutes

Why Choose Us

  • Global & Local Expertise
  • Prospective Attendees
  • Larger worldview of the profession
  • We’re passionate about what we do
  • We focus on your career growth
  • Transparency in Communication
  • Open gateway towards INNOVATION
  • Strong sense of identification
  • Quality without compromise
  • Highly organised and structured scientific programs

Key Takeaways

  • CME / CNE / CPE / CDE Credits
  • Professional Worldwide
  • International Recognition of Researchers
  • Knowledge into Asset
  • Cognizance of leading Cutting – Edge technologies
  • Publication of Abstracts in preeminent supported journals
  • New Accomplishments with Edu – tech ideas
  • Exposure to the upcoming business trends
  • Free access to our forthcoming International events
  • Certificate of presentation with International signatories

United Pharma Technologies Collaborations and Associations

Biography: Executive director at Ketotic Hypoglycemia International. Her work started with the establishment of an international patient association where they are in close collaboration with national and international researchers, have written scientific papers and conducted research projects using a Citizen Science approach. Most recently, she entered the European Health Parliament and the European Medicines Agency as a Patient Representative for patients with rare hypoglycemia diseases. Furthermore, she have been working for EURORDIS (European Organization for Rare Diseases) to develop recommendations for Europes' rare disease policy in the Rare2030 project.
Marieke Meulemans
CEO GCP Central B.V., Amsterdam, North Holland, Netherlands
Biography: She is a Founder and CEO of GCP Central since 2012 with over 15 years of experience within the clinical research world, and is the driving force behind the company vision.

Expertise:
•Development of practice-based and effective online GCP training for clinical research professionals.
•Setup and implementation of Learning Management Systems.

Specialties: eLearning development ; online GCP training; training needs analysis; process improvement; training management; blended learning; Good Clinical Practice; Clinical research rules & regulations; Wet Medisch Wetenschappelijk Onderzoek (WMO) training
Hayley Lewis
Senior Vice President, Operations at Zosano Pharma, San Francisco Bay Area, California
Biography: Hayley Lewis serves as our Senior Vice President of Operations, where she oversees the functional areas of Nonclinical, R&D, Analytical Development and QC, Operations and Engineering, Manufacturing, and Regulatory Affairs, and continues to be responsible for overseeing all regulatory interactions with the FDA and other government agencies. Hayley joined the company as the Vice President of Regulatory Affairs and Quality in October 2015.
Prior to joining Zosano, Hayley spent over 11 years in Regulatory Affairs at Depomed, Inc., a specialty pharmaceutical company, where she was involved in the approval of 3 commercial products. Over the course of her career, she has enabled 8 investigational products to be studied in humans, 5 of which have advanced to completion of Phase 3 trials. Hayley’s pharmaceutical development experience, spanning over 20 years, covers solid oral dosage forms, and combination products such as systemic and local inhalation products, a single entity combination injectable, and transdermal systems. Ms. Lewis received a B.S. in Pharmaceutical Sciences from the University of Greenwich in England, and has attained several management diplomas from Kellogg School of Management, as well as Stanford’s Graduate School of Business.
Biography: Fengzhi Li became a faculty member at Roswell Park Comprehensive Cancer Center (legal name: Roswell Park Cancer Institute, the first cancer institution in the US history and is a US NCI-designated comprehensive cancer center) in 2001 after finishing his postdoctoral training in Dr. Dario C. Altieri’s laboratory at Boyer Center for Molecular Medicine, Yale Medical School where he focused his research on the characterization of the function and expression regulation of a newly discovered antiapoptotic protein named survivin (a novel member of the inhibitor of apoptosis protein family). In 2006 he has been promoted to Associate Professor of Oncology at Roswell Park. As a chief scientist, he leads his lab using the survivin gene as a target and biomarker for targeted drug discovery. He has transitioned his Roswell Park cancer research lab from basic to translational cancer research over the past decade. His current research interests focus on targeted anticancer drug discovery, development and mechanism of action (MOA) studies. His research has been supported through federal agencies (NIH/NCI, DOD) as well as other public/private foundations and partnerships. He has published over 80 publications (h-index, 47 and i10-index, 73) with a total citation of over 13,000 times. He is the editorial board members in several academic journals including J Exp Clin Can Res (2019 IF: 7.068), Am J Transl Res (2019 IF: 3.375) and Int J Mol Sci (2019 IF: 4.556). He is also the Chief Scientific Officer (CSO) of Canget BioTekpharma LLC (www.canget-biotek.com) and helps Canget to develop innovative targeted anticancer drugs (high efficacy with low toxicity) for benefiting cancer patients.
Anup Madan
Director, Biomarkers at PPD
Greater Seattle Area, Washington, USA.
Biography: Highly-motivated and proactive leader with a passion to collaborate effectively with all necessary team members, both internal and externally, for delivering life-changing therapies to patients. Extensive expertise in translational oncology, biomarker research and business administration. Strong knowledge in computational biology, and data mining, experienced in pre-clinical and clinical genomics. Creative thinker and problem solver; rapidly adapts to new projects and a changing work environment. Highly productive in matrix organizations or independent working environments. Strong ability to work cross functionally to define and implement strategies that impact decision making. Possesses excellent communication, and presentation skills.

Submit Manuscript

Manuscript Details

Author Details